ECD Global Alliance
The Erdheim-Chester Disease Global Alliance is an ultra-rare disease patient advocacy group dedicated to raising awareness, providing support to those affected by the disease, educating the medical community with material, facilitating information sharing among interested parties regarding ECD, and advocating for and financially supporting research programs related to Erdheim-Chester Disease. Please contact us for more information.
Please join the ECD Global Alliance at www.erdheim-chester.org to learn more about ECD and to hear about upcoming events.
Giving Tuesday is Coming Soon
Understanding Erdheim-Chester Disease: The Molecular and Clinical Landscape
Survivorship in Erdheim-Chester Disease: Incorporating the patient voice
Erdheim-Chester Disease: Evolving Insights and Improved Survival | Medical Symposium 2025
Second Cancer in Erdheim-Chester Disease | Francesco Pegoraro | Medical Symposium 2025
Natural History of ECD: Analysis of 1044 Patients in the ECDGA Network | Medical Symposium 2025
Advanced Proteomic Profiling for Biomarker Discovery in ECD | Medical Symposium 2025
Diagnostic Impact of 18F-FDG PET/MRI vs PET/CT in Histiocytosis | Medical Symposium Barcelona 2025
Deciphering ALK-positive Histiocytosis and Mimickers with Single Cell RNA Sequencing | ECDGA 2025
Mapping Erdheim-Chester Disease in Europe through the Core Registry | Medical Symposium 2025
BCL-2 Immunohistochemistry Expression in Patients with Histiocytosis | ECD Medical Symposium 2025
Car T-Cell Immunotherapies Beyond Hematological Cancers | ECDGA Medical Symposium 2025
Layers of Complexity: ECD Diagnosis and Management with Comorbidities | Medical Symposium 2025
Glomeruloid Angioma in ECD: Atypical Skin Manifestation Linked to Elevated VEGF-A | ECDGA 2025
MAPK-Kinase Mutations, Aortic Lesions, and Circulating Monocytes in Histiocytosis | ECDGA 2025
Comparative Genetic Analysis of Primary vs Secondary Histiocytic Sarcoma | Medical Symposium 2025
Real-World Efficacy and Toxicity of MEK Inhibitors in Histiocytic Neoplasms | Medical Symposium 2025
RAF-Independent MEK Mutations in Histiocytic Neoplasms and ERK Inhibition | Medical Symposium 2025
ECD Global Alliance Into the Future | Medical Symposium 2025
Symptoms, Unmet Needs, and Quality of Life in ECD: Registry-Based Analysis | Medical Symposium 2025
The Clonal Origin and Evolution of High-Risk Multisystem Histiocytosis in Adults | ECDGA 2025
Treatment Holidays in Patients with ECD Receiving Vemurafenib | Medical Symposium 2025
Targeted Therapies vs Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms | ECDGA 2025
Don’t Dish Out Old Therapies: Pegylated Interferon-Alpha in Erdheim-Chester | ECDGA Symposium 2025
Welcome to the 2025 ECDGA Medical Symposium | Barcelona (Part A)
Welcome to the 2025 ECDGA Medical Symposium | Barcelona (Part B)
Meet Edith & Mike Watters: Fighting for Hope, One Fundraiser at a Time
Managing Diabetes Insipidus (AVP-D): Practical Guidance from a Patient-Expert